FDA Approves Acalabrutinib With Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
FDA Approves Novocure’s Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer
FDA Approves Pembrolizumab With Paclitaxel for Platinum-resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With Dihydropyrimidine Dehydrogenase Deficiency
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
FDA Approves Daratumumab and Hyaluronidase-fihj With Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Sun Pharma Announces the Availability of Cosibelimab-ipdl for Advanced Cutaneous Squamous Cell Carcinoma
FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection
FDA Grants Regular Approval to Rucaparib for Metastatic Castration-resistant Prostate Cancer
FDA Approves Fam-trastuzumab Deruxtecan-nxki With Pertuzumab for Unresectable or Metastatic HER2-positive Breast Cancer
FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-sensitive Prostate Cancer
FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma
FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
FDA Approves Durvalumab for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer
FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer
FDA Grants Accelerated Approval to Sevabertinib for Non-squamous Non-small Cell Lung Cancer
FDA Grants Traditional Approval to Daratumumab and Hyaluronidase-fihj for Newly Diagnosed Light Chain Amyloidosis
FDA Approves Epcoritamab-bysp for Follicular Lymphoma Indications
FDA Approves New Interchangeable Biosimilar to Perjeta
FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukemia With a NPM1 Mutation
FDA Approves Daratumumab and Hyaluronidase-fihj for High-risk Smoldering Multiple Myeloma
FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
Abemaciclib Shows Prolonged Survival in HR+, HER2-, High-risk Early Breast Cancer With 2 Years of Treatment
FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
FDA Approves Lurbinectedin in Combination With Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive-stage Small Cell Lung Cancer
FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer
FDA Approves Pembrolizumab and Berahyaluronidase Alfa-pmph for Subcutaneous Injection
FDA Approves Selumetinib for Select Pediatric Patients 1 Year of Age and Older
FDA Approves Gemcitabine Intravesical System for Non-muscle Invasive Bladder Cancer
